Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periarticular cocktail injection with two doses of triamcinolone in total hip arthroplasty
IRCT20221029056333N4Phase 3Recruiting
- Sponsor
- Babol University of Medical Sciences
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of triamcinolone, tranexamic acid and bupivacaine in hip osteoarthritis (3 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Pain intensity. Started Sep 2026; status: recruiting.
02
Drugs
triamcinolonetranexamic acidbupivacaine
03
Conditions
hip osteoarthritis
Beyond the preview
Go deeper on IRCT20221029056333N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221029056333N4.